Roche Korea names Kang Hyun-ju as new A&P Cluster lead
Roche Korea said Thursday that it has appointed Director Kang Hyun-ju as the new leader of its Access & Policy (A&P) Cluster.
As the new head of the A&P cluster, which is responsible for policy-related discussions with various stakeholders, including the government, to improve patients' access to innovative medicines, Kang has accumulated a wide range of experience and capabilities in reimbursement and drug pricing policies since joining Roche Korea in 2000, working in the Market Access (MA), Regulatory Affairs, and Quality Assurance departments.
Notably, she served as the MA Chapter lead until her appointment, where she led the successful reimbursement of Roche's innovative medicines globally by creating a strategic environment and facilitating communication with various stakeholders in the government and private sector.
Following the coverage expansion of targeted anticancer drug Kadcyla for early breast cancer in 2022, immuno-oncology drug Tecentriq for first-line treatment of non-small cell lung cancer, and cancer-specific treatment Rozlytrek, Kang oversaw the coverage strategy for 11 medicines, including neurological and rare diseases including Enspryng and Evrysdi, and macular degeneration treatment Vabysmo in 2023, contributing to expanding access to new treatment options and improving the treatment environment for Korean patients.
With more than 20 years of extensive and agile policy response experience at Roche Korea, Kang will work to advance the Korean healthcare landscape and introduce innovative solutions that deliver greater societal value to patients.
"Based on my expertise, I will continue to actively engage with various stakeholders, including the government and patients, to contribute to the rapid introduction and reimbursement of Roche's innovative medicines to improve patient access," Kang said.
Kang graduated from Yeungnam University College of Pharmacy and earned a master's degree in health policy from Yonsei University Graduate School of Public Health.